Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous methylnaltrexone for opioid-induced constipation in adults with cancer-related pain
2008-005692-10Phase 4Completed
- Sponsor
- Wyeth
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Methylnaltrexone bromide with Placebo (2 arms). Primary endpoint: Proportion of subjects with a rescue-free bowel movement within 4 hours after the first dose of study drug. Started Jan 2009; status: completed.
02
Drugs
methylnaltrexone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2008-005692-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005692-10.